AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Autolus Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.59−0.01 (-0.63%)
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
-27.8%
Operating margin
-358.9%
Net margin
-381.4%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +644.9% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -95.0% | |
| Return on assets | – | – | -41.9% | |
| Current ratio | – | 5.86 | 5.94 | |
| Debt to equity | – | – | – | |
| Interest coverage | – | – | -7.4× | |
| Inventory turnover | – | – | 5.2× | |
| Capex to revenue | – | – | 25.3% | |
| Diluted shares | – | 52M | 266M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Autolus Therapeutics generated $865.60M from operations and spent $71.80M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$865.60M
Used
$71.80M
Capital expenditure$71.80M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-381.4%
×Asset turnover0.11×
×Equity multiplier2.27×
=Return on equity, FY2025-95.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -381.4% | 0.11× | 2.27× | -95.0% |
| FY2024 | -2180.5% | 0.02× | 2.15× | -81.9% |
| FY2023 | -12272.3% | 0.00× | 2.11× | -101.6% |
| FY2018 | -3180.6% | 0.01× | 1.06× | -22.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$287.53M
- Cash generatingOperating cash flow above zero-$283.57M
- Return on assets improvedROA up on the prior year-58.8% → -36.7%
- Earnings backed by cashOperating cash flow above net income-$283.57M vs -$287.53M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.88 → 5.94
- No dilutionShare count did not rise255M → 266M
- Gross margin improvedGross margin up on the prior year-12.52% → -27.83%
- More efficientAsset turnover rose0.03 → 0.10